The Journal of Clinical Hypertension, 2022 Growing evidences have confirmed the effect of Sacubitril/Valsartan (SV) on antihypertension and cardiac protection in general population. However, there was no prospective study about the effect and safety of SV on resistant hypertension and myocardial ...
Bin Wang +6 more
semanticscholar +1 more source
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation
JAMA cardiology, 2022 This prespecified analysis of the Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN TRIO) randomized clinical trial investigates if the blood pressure–lowering effect of ultrasound renal denervation in patients with ...
M. Azizi +21 more
semanticscholar +1 more source
Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight
International Journal of Molecular Sciences, 2022 Primary aldosteronism (PA) is a pathological condition characterized by an excessive aldosterone secretion; once thought to be rare, PA is now recognized as the most common cause of secondary hypertension.
F. Bioletto +8 more
semanticscholar +1 more source
RESISTANT ARTERIAL HYPERTENSION
Евразийский Кардиологический Журнал, 2018 Resistant hypertension is defined as a lack to lower 140 mmHg (systolic blood pressure) and 90 mmHg (diastolic blood pressure) values of ambulatory blood pressure (BP) response using 3 antihypertensive agents of different classes, one of which should be ...
T. E. Esaulova +3 more
doaj +1 more source
Aprocitentan and the endothelin system in resistant hypertension.
Canadian Journal of Physiology and Pharmacology, 2022 Endothelin has emerged as a target for therapeutic intervention in systemic hypertension. As a vasoconstrictor, co-mitogenic agent, linking pulse pressure and vascular remodeling, and mediator of aldosterone and catecholamine release, endothelin is a key
M. Clozel
semanticscholar +1 more source
The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience [PDF]
, 2017 The prevalence of resistant hypertension (RHT) still remains unknown. Aim of the study was to investigate in a large cohort of hypertensive patients the prevalence of RHT, and to identify in these patients the secondary forms of arterial hypertension (SH)
Concistre, Antonio +13 more
core +2 more sources
Long-term outcome of renal nerve denervation (RDN) for resistant hypertension
Hypertension Research, 2022 We aimed to determine the long-term outcome of renal denervation (RDN). All patients with resistant hypertension who underwent RDN between 2012 and 2018 at Siriraj Hospital were included in the study.
Pariya Panchavinnin +8 more
semanticscholar +1 more source
Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995-2015. [PDF]
, 2017 Objective To estimate the incidence and prevalence of resistant hypertension among a UK population treated for hypertension from 1995 to 2015.Design Cohort study.Setting Electronic health records from the UK Clinical Practice Research Datalink in primary
Douglas, Ian J +3 more
core +1 more source
Resistant hypertension: Prevalence and profile of patients followed in a university ambulatory
SAGE Open Medicine, 2021 Background: Hypertension affects about 36 million Brazilians. It is estimated that 10%–20% of these have resistant hypertension. These patients are at an increased risk of early target organ damage, as well as cardiovascular and renal events.
Ana Flávia Moura +8 more
doaj +1 more source
Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension [PDF]
, 2010 Resistant hypertension is defined as failure to lower blood pressure to target when a patient adheres to the maximum tolerated doses of three antihypertensive drugs including a diuretic.
Enseleit, F +2 more
core +1 more source